Heat shock proteins, such as HSP40, HSP60, HSP70 and HSP90, are known as molecular chaperones because they play a role in helping proteins function properly when cells are under stress. The heat shock response protects cells from the accumulation of misfolded proteins, aggregated proteins, and dysfunctional lysosomes (the cell’s recycling system), which could otherwise lead to toxicity and disease.
Our work is focused on making use of the cell-protective properties of HSP70 to create new therapies for rare neurodegenerative diseases.
Orphazyme A/S Company announcement No. 21/2021 Company Registration No. 32266355 Copenhagen – June 28 , 20 2 1 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company, today announced 24-month interim results of an open-label extension (OLE) trial, providing efficacy and
Orphazyme A/S Company announcement No. 20/2021 Inside information Company Registration No. 32266355 - Significant h eadcount reduction of global workforce to free resources - -Changes to the B oard of D irectors- - O utlook for 2021 reiterated - Copenhagen – June 28, 2021 – Orphazyme A/S
Orphazyme A/S Company announcement No. 16/2021 Inside information Company Registration No. 32266355 Copenhagen – June 18 , 2021 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of rare diseases, today
Our Research
For Investors & Media
Working at Orphazyme